Business & Finance

Anthropic's IPO filing puts life sciences at the center of growth strategy

Business Insider reports that Anthropic's S-1 filing ahead of its IPO highlights pharma customers and a $400 million biotech acquisition.

Updated Oct 31, 2026 · 12:32 UTC3 reports

The short version

Anthropic's S-1 filing, ahead of a planned IPO, presents life sciences as central to its business strategy and growth.[Business Insider]
Nine of the 10 largest pharmaceutical companies and eight of the 10 largest healthcare firms in the Fortune 500 each spent at least $100,000 with Anthropic over a recent yearlong period, according to the filing.[Business Insider]
Anthropic has released Claude Science in beta, opened a Bay Area molecular biology lab, and bought Coefficient Bio for $400 million in stock.[Business Insider]
Anthropic declined to comment, and no AI-designed drug has ever received FDA approval.[Business Insider]

Anthropic's S-1 filing outlines its ambitions and financials ahead of an initial public offering scheduled for next month.[Business Insider]
Nine of the 10 largest pharmaceutical companies and eight of the 10 largest healthcare companies in the Fortune 500 spent at least $100,000 with Anthropic over a recent yearlong period.[Business Insider]
Anthropic spent $400 million in stock in April to acquire the biotech startup Coefficient Bio.[Business Insider]
Vas Narasimhan, CEO of Novartis, joined Anthropic's board of directors in April.[Business Insider]
Anthropic's Claude Science product, which is in beta, was released in June.[Business Insider]
No AI-designed drugs have ever received FDA approval.[Business Insider]

Figures on customer spending, employee usage and survey results come from Anthropic's own filing and have not been independently verified in the reporting; Anthropic declined to comment.[Business Insider]
The reporting does not quantify how much revenue life sciences currently contributes to Anthropic.[Business Insider]

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.